BACKGROUND: The USA300 strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) can cause severe infection and is increasingly recognized as a cause of community outbreaks. In 2004, an outbreak was identified in the Calgary Health Region (CHR). METHODS: MRSA isolates were identified with standard methods at a central regional laboratory and typed via pulsed-field gel electrophoresis (PFGE). Isolates were tested by PCR for mecA, Panton-Valentine leukocidin (PVL), SCCmec, and spa genes. Cases were defined as such if a clinical isolate of the USA300 strain was noted between January 1 and September 30, 2004, and the patient had lived or traveled in CHR within 2 years before symptom onset. Demographic, clinical and risk data on all such cases were collected from several sources for statistical analysis. A case was defined as high-risk if the patient had a history of drug use, homelessness or incarceration. RESULTS: Of 40 isolates with the USA300 PFGE pattern, all tested positive for PVL, SCCmec type IVa and spa type 008. Almost all infections (39/40, 98%) involved skin and soft tissues, except for 1 death from necrotizing hemorrhagic pneumonia; a notable proportion (38%) required hospital admission or intravenous antimicrobial therapy. The outbreak centred on the high-risk population in CHR (70%; risk ratio 169.4, 95% confidence interval 86.1-333.0). INTERPRETATION: People with histories of illicit drug use, homelessness or recent incarceration were at highest risk for infection with CA-MRSA. The emergence and spread of this virulent strain has important implications for treatment and public health in Canada.
BACKGROUND: The USA300 strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) can cause severe infection and is increasingly recognized as a cause of community outbreaks. In 2004, an outbreak was identified in the Calgary Health Region (CHR). METHODS: MRSA isolates were identified with standard methods at a central regional laboratory and typed via pulsed-field gel electrophoresis (PFGE). Isolates were tested by PCR for mecA, Panton-Valentine leukocidin (PVL), SCCmec, and spa genes. Cases were defined as such if a clinical isolate of the USA300 strain was noted between January 1 and September 30, 2004, and the patient had lived or traveled in CHR within 2 years before symptom onset. Demographic, clinical and risk data on all such cases were collected from several sources for statistical analysis. A case was defined as high-risk if the patient had a history of drug use, homelessness or incarceration. RESULTS: Of 40 isolates with the USA300 PFGE pattern, all tested positive for PVL, SCCmec type IVa and spa type 008. Almost all infections (39/40, 98%) involved skin and soft tissues, except for 1 death from necrotizing hemorrhagic pneumonia; a notable proportion (38%) required hospital admission or intravenous antimicrobial therapy. The outbreak centred on the high-risk population in CHR (70%; risk ratio 169.4, 95% confidence interval 86.1-333.0). INTERPRETATION:People with histories of illicit drug use, homelessness or recent incarceration were at highest risk for infection with CA-MRSA. The emergence and spread of this virulent strain has important implications for treatment and public health in Canada.
Authors: John S Francis; Meg C Doherty; Uri Lopatin; Cecilia P Johnston; Gita Sinha; Tracy Ross; Mian Cai; Nadia N Hansel; Trish Perl; John R Ticehurst; Karen Carroll; David L Thomas; Eric Nuermberger; John G Bartlett Journal: Clin Infect Dis Date: 2004-12-07 Impact factor: 9.079
Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948
Authors: Sophia V Kazakova; Jeffrey C Hageman; Matthew Matava; Arjun Srinivasan; Larry Phelan; Bernard Garfinkel; Thomas Boo; Sigrid McAllister; Jim Anderson; Bette Jensen; Doug Dodson; David Lonsway; Linda K McDougal; Matthew Arduino; Victoria J Fraser; George Killgore; Fred C Tenover; Sara Cody; Daniel B Jernigan Journal: N Engl J Med Date: 2005-02-03 Impact factor: 91.245
Authors: B Shopsin; M Gomez; S O Montgomery; D H Smith; M Waddington; D E Dodge; D A Bost; M Riehman; S Naidich; B N Kreiswirth Journal: J Clin Microbiol Date: 1999-11 Impact factor: 5.948
Authors: David M Young; Hobart W Harris; Edwin D Charlebois; Henry Chambers; Andre Campbell; Françoise Perdreau-Remington; Chen Lee; Mahesh Mankani; Robert Mackersie; William P Schecter Journal: Arch Surg Date: 2004-09
Authors: Michael W Ellis; Duane R Hospenthal; David P Dooley; Paula J Gray; Clinton K Murray Journal: Clin Infect Dis Date: 2004-09-02 Impact factor: 9.079
Authors: Jessica H Leibler; Casey León; Lena J P Cardoso; Jennifer C Morris; Nancy S Miller; Daniel D Nguyen; Jessie M Gaeta Journal: J Med Microbiol Date: 2017-08 Impact factor: 2.472
Authors: Andrew E Simor; Lisa Louie; Christine Watt; Denise Gravel; Michael R Mulvey; Jennifer Campbell; Allison McGeer; Elizabeth Bryce; Mark Loeb; Anne Matlow Journal: Antimicrob Agents Chemother Date: 2010-03-15 Impact factor: 5.191
Authors: M Sassi; B Felden; M Revest; P Tattevin; Y Augagneur; P-Y Donnio Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-02 Impact factor: 3.267